Scarica l'app Stockscreener
26.19
2.96%
-0.80
Dopo l'orario di chiusura:
26.19
Precedente Chiudi:
$26.99
Aprire:
$25.81
Volume 24 ore:
1.39M
Relative Volume:
1.09
Capitalizzazione di mercato:
$2.07B
Reddito:
-
Utile/perdita netta:
$-171.36M
Rapporto P/E:
-8.8537
EPS:
-2.9581
Flusso di cassa netto:
$-171.37M
1 W Prestazione:
-1.50%
1M Prestazione:
-5.11%
6M Prestazione:
-29.41%
1 anno Prestazione:
+94.00%
Intervallo 1D:
$25.45
$28.65
Intervallo di 1 settimana:
$24.37
$31.00
Portata 52W:
$10.44
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
26.19 | 2.07B | 0 | -171.36M | -171.37M | -2.9581 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Insider Monkey
Jefferies cuts Mineralys Therapeutics price target on drug concerns By Investing.com - Investing.com Australia
Jefferies cuts Mineralys Therapeutics price target on drug concerns - Investing.com
Stifel reiterates Buy rating on Mineralys stock, $52 target By Investing.com - Investing.com Nigeria
BofA raises Mineralys Therapeutics stock price target on NDA progress By Investing.com - Investing.com Nigeria
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha
Mineralys Therapeutics price target raised to $51 from $46 at BofA - TipRanks
Stifel reiterates Buy rating on Mineralys stock, $52 target - Investing.com
BofA raises Mineralys Therapeutics stock price target on NDA progress - Investing.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight - GuruFocus
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Ins - GuruFocus
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - Bitget
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c) - TipRanks
Mineralys Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast - Investing.com
Mineralys Therapeutics and Lorundrostat: Clinical Development, Competitive Landscape, and Regulatory Overview for Hypertension Therapy 2122273536 - Minichart
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Mineralys Therapeutics 10-K: $0 Revenue, $(2.29) EPS - TradingView
MINERALYS THERAPEUTICS ($MLYS) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss - marketscreener.com
David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions - Stock Titan
FDA accepts Mineralys (NASDAQ: MLYS) NDA for lorundrostat in hypertension - Stock Titan
Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026 - Stock Titan
Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings - TipRanks
Mineralys Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Mineralys earnings in focus as FDA lorundrostat decision looms By Investing.com - Investing.com Australia
Mineralys earnings in focus as FDA lorundrostat decision looms - Investing.com
How Investors Are Reacting To Mineralys Therapeutics (MLYS) FDA Acceptance Of Lorundrostat Hypertension NDA - simplywall.st
Capital International Investors Sells 505,624 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data By Investing.com - Investing.com UK
Mineralys Shares Climb After FDA Accepts NDA for Blood Pressure Medication - Bitget
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat
Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise - Stock Titan
3 Reasons Not to Sleep on ResMed Stock - AOL.com
H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance - Investing.com UK
Mineralys blood pressure drug under FDA review (MLYS:NASDAQ) - Seeking Alpha
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap DownHere's What Happened - MarketBeat
H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance By Investing.com - Investing.com India
Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data - Investing.com India
Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):